2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

BM cells

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

MCE Kits

1

Inhibitory Antibodies

1

Natural
Products

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-169925
    BM-962

    		Bcl-2 Family Cancer
    BM-962 (Compound 31) is a potent small-molecule inhibitor of Bcl-2 with an IC50 value of 4 nM (Ki=0.8 nM) and Bcl-xL with an IC50 value of 3.9 nM (Ki <1 nM). BM-962 inhibits the cell growth in H1417 and H146 cell lines with IC50 values of 9 and 13 nM, respectively. BM-962 is promising for research of cancers .
    BM-962
  • HY-109061B
    Lazertinib mesylate
    1 Publications Verification

    YH25448 mesylate; GNS-1480 mesylate

    		 EGFR Akt ERK Cancer
    Lazertinib (mesylate) (YH25448 (mesylate); GNS-1480 (mesylate)) is an orally active EGFR inhibitor that can penetrate the blood-brain barrier. Lazertinib (mesylate) inhibits p-EGFR, p-AKT and p-ERK signaling pathways, leading to apoptosis. Lazertinib (mesylate) has anti-tumor activity in the mouse H1975-luc BM xenograft model. Lazertinib (mesylate) can be used in the study of non-small cell lung cancer .
    Lazertinib mesylate
  • HY-121018
    Daltroban

    BM-13505; SKF 96148

    		 Prostaglandin Receptor Cardiovascular Disease
    Daltroban (BM-13505) is a selective and specific thromboxane A2 (TXA2) receptor antagonist. Daltroban increase intracellular calcium in vascular smooth muscle cells. Daltroban shows protective effect in reperfusion injury .
    Daltroban
  • HY-B0515
    Ibandronate Sodium Monohydrate

    BM-210955; RPR-102289A

    		 Apoptosis Metabolic Disease Cancer
    Ibandronate Sodium Monohydrate (BM-210955; RPR-102289A) is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase). Ibandronate Sodium Monohydrate can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS, RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate Sodium Monohydrate inhibits tumor cell proliferation (such as ER + breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate Sodium Monohydrate is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis) .
    Ibandronate Sodium Monohydrate
  • HY-B0004
    Doxofylline

    		Adenosine Receptor Phosphodiesterase (PDE) Reactive Oxygen Species (ROS) Inflammation/Immunology
    Doxofylline is an orally active PDE IV inhibitor and A1AR antagonist. Doxofylline reduces inflammation in epithelial cells via inhibiting mitochondrial ROS production and amelioration of multiple cellular pathways (NLRP3-TXNIP inflammasome activation). Doxophylline can be used in studies of asthma, chronic obstructive pulmonary disease, and bronchospasm .
    Doxofylline
  • HY-13846
    BM-1074

    		Bcl-2 Family Apoptosis Cancer
    BM-1074 is a potent and specific Bcl-2/Bcl-xL inhibitor with Ki values of < 1 nM and IC50 values of 1.8 nM and 6.9 nM for Bcl-2 and Bcl-xL, respectively. BM-1074 induces apoptosis, and exhibits antiproliferative activity against four small-cell lung cancer cell lines (H146, H1963, H187 and H1417) with IC50 values of 1-2 nM .
    BM-1074
  • HY-B0515R
    Ibandronate Sodium Monohydrate (Standard)

    BM-210955 (Standard); RPR-102289A (Standard)

    		 Reference Standards Apoptosis Cancer
    Ibandronate Sodium Monohydrate (BM-210955; RPR-102289A) (Standard) is the analytical standard of Ibandronate Sodium Monohydrate (HY-B0515). This product is intended for research and analytical applications. Ibandronate Sodium Monohydrate (BM-210955; RPR-102289A) is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase). Ibandronate Sodium Monohydrate can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS, RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate Sodium Monohydrate inhibits tumor cell proliferation (such as ER + breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate Sodium Monohydrate is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis) .
    Ibandronate Sodium Monohydrate (Standard)
  • HY-N7291
    Tryprostatin A

    		Others Others
    Tryprostatin A is an inhibitor of the mammalian cell cycle. Tryprostatins A can be isolated from the secondary metabolites of a marine fungal strain BM939 .
    Tryprostatin A
  • HY-133838
    Ilmofosine

    BM41440

    		 Parasite PKC Infection Cancer
    Ilmofosine (BM41440) is a potent and selective protein kinase C inhibitor. Ilmofosine induces cell cycle arrest at the G2 phase. Ilmofosine also is an anti-leishmanial agent .
    Ilmofosine
  • HY-117008
    CAY10589

    		PGE synthase Inflammation/Immunology
    CAY10589 is an inhibitor of mPGES-1, an enzyme induced during inflammatory responses. CAY10589 has no significant effect on the differentiation of BM myeloid precursor cells into M2-like TAMs .
    CAY10589
  • HY-B0004R
    Doxofylline (Standard)

    		Reference Standards Adenosine Receptor Phosphodiesterase (PDE) Reactive Oxygen Species (ROS) Inflammation/Immunology
    Doxofylline (Standard) is the analytical standard of Doxofylline. This product is intended for research and analytical applications. Doxofylline is an orally active PDE IV inhibitor and A1AR antagonist. Doxofylline reduces inflammation in epithelial cells via inhibiting mitochondrial ROS production and amelioration of multiple cellular pathways (NLRP3-TXNIP inflammasome activation). Doxophylline can be used in studies of asthma, chronic obstructive pulmonary disease, and bronchospasm .
    Doxofylline (Standard)
  • HY-P99536
    Tagraxofusp

    SL-401

    		 Interleukin Related Cancer
    Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib (HY-10227) and Pomalidomide (HY-10984) to suppress multiple myeloma (MM) .
    Tagraxofusp
  • HY-177058
    DSP30

    		Toll-like Receptor (TLR) Mitosis Inflammation/Immunology
    DSP30 is a phosphorothioate cpG-oligodeoxynucleotide and a TLR9 agonist. DSP30 can activate immune system cells, including B cells and dendritic cells, by inducing proliferation and cytokine production.DSP30 can enhance the immunosuppressive function of bone marrow-multipotent mesenchymal stromal cells (BM-MSC). DSP30 combined with interleukin 2 (IL2) is an effective mitotic stimulant in B-cell disorders. DSP30 can be used for the genetic characteristic research and analysis of chronic lymphocytic leukemia (CLL) .
    DSP30
  • HY-108298
    Perfluorodecalin

    PP 5; Perfluorodecahydronaphthalene

    		 Biochemical Assay Reagents Others
    Perfluorodecalin liquids are largrly used in vitreoretinal surgery. Perfluorodecalin with tamponade lasting more than two days is detrimental to the retina in the case of rabbit. Perfluorodecalin can be used for the research of giant retinal tears . Perfluorodecalin is a non-toxic, non-flammable, thermally stable, non-bio-accumulating O2-carrier and used as artificial blood . Perfluorodecalin enhances bone regeneration and cell viability .
    Perfluorodecalin
  • HY-117947
    (R)-OR-S1

    		Histone Methyltransferase Cancer
    (R)-OR-S1 is an isomer of OR-S1. The dual ZH1/2 inhibitors OR-S1 and OR-S2 exhibit strong inhibitory activity against both EZH1 and EZH2. OR-S1 and OR-S2 are highly selective methyltransferase inhibitors against EZH1 and EZH2, and they have very similar molecular features. Therefore, we investigated the effect of OR-S1 on acute myeloid leukemia (AML). We found that OR-S1 was able to induce cell differentiation and apoptosis in AML cells. These findings encouraged us to investigate whether functional LT-HSCs could survive PRC2-targeted therapy with OR-S1 or OR-S1 combined with cytarabine. The results showed that OR-S1 did not cause significant myelosuppression, and BM cells treated with the combination therapy were able to undergo normal hematopoiesis even 4 months after treatment. Therefore, temporary inhibition of EZH1 and EZH2 is clinically tolerable, making this combination therapy suitable for AML patients. AML is generally believed to originate from myeloid progenitor cells that inherit a large number of biological properties.
    (R)-OR-S1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: